The inventive technology includes novel systems, methods, and compositions for the generation of water-soluble short-chain fatty acid phenolic compounds, preferably cannabinoids, terpenes, and other volatile compounds produced in Cannabis and other cannabinoid producing plants. In particular, the inventive technology includes novel systems and methods to solubilize short-chain fatty acid phenolic compounds, such as cannabinoids, via binding to a water soluble and readily digested carrier protein.

The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

The present invention relates to recombinant Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

Provided are an anti-PSMA single-chain antibody, a chimeric antigen receptor associated therewith and use thereof. An amino acid sequence of a heavy chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 1, and an amino acid sequence of a light chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 2. The anti-PSMA single-chain antibody is a humanized scFv antibody of PSMA, is more functional in the human body, has better compatibility, and is less prone to be rejected by the immune system. The chimeric antigen receptor has better response effects after specifically bonding to PSMA so that CAR-T cells generate a stronger immune response to tumors, and the chimeric antigen receptor also has better long-term effectiveness than other PSMA chimeric antigen receptors.

The present disclosure provides, in one aspect, specific doses of an ENPP1 agent for in vivo treatment of Diffuse idiopathic skeletal hyperostosis (DISH), Ankylosing Spondylitis, and/or Spondylarthritis.

This disclosure provides expression systems comprising secretion signals that promote production and/or secretion of proteins of interest, as well as one or more polynucleotides encoding chaperone proteins (e.g., CRT and/or PDIA3) which, as demonstrate herein, enhance production and/or secretion of proteins. Moreover, genetically modified host cells comprising these expression systems are capable of producing high levels of protein of interest, such as bovine lactoferrin (bLF), bovine lactoglobulin (bLG), or ovalbumin (Ova).

Methods and compositions comprising recombinant fusion polypeptides that are engineered to allow for heterologous cargo secretion from a Bacteroides cell, into an extracellular environment are provided. Provided methods and compositions include recombinant fusion polypeptides comprising a secretion domain and a heterologous cargo domain. Methods and compositions for using said recombinant fusion polypeptides, e.g., for the treatment of a disease and/or disorder, are also provided.

The present disclosure provides materials and methods related to the production of peptides and polypeptides from engineered microorganisms. In particular, the present disclosure provides compositions and methods for producing a genetically modified microorganism (e.g., yeast cell) with enhanced protein expression and/or secretion.